Health Status and Patient Satisfaction after Corneal Graft: Results from the Corneal Transplant Epidemiological Study

Table 4

PCS-12 and MCS-12 (mean and 95% CI) and effect size (ES) by subgroups.

		PCS-12			MCS-12
	𝑁	𝑇0	𝑇1	ES^∗	𝑇0	𝑇1	ES*
Total	1,223	50.8 (50.4–51.2)	50.2 (49.8–50.6)	0.09	48.4 (47.8–49.0)	50.4 (49.8–51.0)	0.19
Gender
Male	719	51.5 (51.0–51.9)	51.4 (50.9–51.9)	−0.01	50.8 (50.1–51.4)	52.4 (51.7–53.1)	0.18
Female	504	49.9 (49.3–50.6)	48.5 (47.8–49.2)	−0.18	45.0 (44.0–46.0)	47.6 (46.6–48.6)	0.23
Male, age groups (y)
18–24	88	52.8 (51.5–54.2)	52.5 (51.3–53.7)	−0.06	49.8 (47.8–51.9)	51.0 (48.9–53.0)	0.12
25–34	178	51.9 (51.0–52.8)	52.7 (51.9–53.5)	0.13	50.5 (49.3–51.7)	53.1 (52.0–54.2)	0.33
35–44	155	51.5 (50.6–52.5)	51.5 (50.5–52.6)	—	49.8 (48.2–51.3)	51.2 (49.7–52.6)	0.15
45–54	111	52.1 (50.8–53.3)	51.3 (50.0–52.6)	−0.11	49.3 (47.3–51.2)	51.3 (49.4–53.1)	0.19
55–64	85	50.3 (49.1–51.6)	51.0 (49.7–52.1)	0.10	52.2 (50.1–54.2)	54.9 (53.3–56.6)	0.29
65–74	59	50.8 (49.6–52.1)	48.4 (46.7–50.0)	−0.49	55.0 (53.2–56.8)	54.6 (52.2–57.0)	−0.06
≥75	43	48.4 (46.1–50.7)	49.4 (47.0–51.8)	0.13	52.5 (49.4–55.7)	51.9 (48.1–55.6)	−0.06
Female, age groups (y)
18–24	27	52.6 (50.1–55.1)	52.2 (49.9–54.5)	−0.07	43.6 (39.1–48.2)	50.4 (46.1–54.6)	0.60
25–34	108	50.3 (48.8–51.8)	50.8(49.6–52.0)	0.06	42.1 (40.0–44.2)	45.7 (43.6–47.8)	0.33
35–44	91	51.2 (49.6–52.7)	49.9 (48.3–51.5)	−0.17	44.9 (42.6–47.1)	48.6 (46.4–50.9)	0.35
45–54	101	50.5 (48.9–52.0)	49.4 (48.0–50.8)	−0.14	45.1 (42.9–47.3)	48.0 (45.8–50.2)	0.26
55–64	72	49.8 (48.3–51.3)	47.4 (45.3–49.4)	−0.38	47.6 (44.8–50.3)	48.2 (45.6–50.8)	0.05
65–74	70	48.4 (46.6–50.1)	45.7 (43.6–47.9)	−0.36	48.0 (45.7–50.3)	49.4 (46.2–52.5)	0.14
≥75	35	45.7 (43.1–48.3)	41.6 (38.2–44.9)	−0.52	43.8 (39.9–47.7)	43.3 (39.5–47.0)	−0.05
Marital status
Married	676	51.1 (50.6–51.5)	50.0 (49.4–50.5)	−0.16	48.8 (48.1–49.6)	50.6 (49.8–51.4)	0.17
Single	412	51.3 (50.6–51.9)	51.5 (50.9–52.1)	0.04	48.3 (47.3–49.3)	50.8 (49.9–51.7)	0.24
Widow/divorced	96	47.2 (45.6–48.8)	45.9 (43.9–47.8)	−0.17	45.6 (43.0–48.1)	47.7 (45.2–50.4)	0.17
Education
High school	457	51.2 (50.6–51.8)	51.2 (50.6–51.8)	—	48.1 (47.1– 49.0)	50.1 (49.2–51.0)	0.20
Secondary school	311	51.1 (50.3–51.9)	50.1 (49.4–50.9)	−0.13	48.2 (47.1–49.4)	51.2 (50.0–52.3)	0.28
Primary school	227	49.0 (48.2–49.9)	47.5 (46.4–48.5)	−0.23	49.0 (47.6–50.4)	50.7 (49.2–52.1)	0.16
Degree	143	52.7 (51.8–53.6)	52.4 (51.4–53.4)	−0.05	49.0 (47.4–50.7)	50.6 (49.2–52.1)	0.16
None	22	46.8 (42.6–50.9)	44.9 (41.2–48.5)	−0.19	47.7 (42.9–52.6)	43.1 (37.5–48.7)	−0.39
Working status							0.21
Worker	632	51.7 (51.2–52.2)	51.5 (51.0–52.0)	−0.04	49.2 (48.4–49.9)	51.2 (50.5–52.0)	0.07
Retired	222	49.2 (48.3–50.1)	47.6 (46.6–48.7)	−0.23	50.8(49.5–52.1)	51.5 (50.0–53.0)	0.20
House keeper	181	48.9 (47.8–50.0)	47.8 (46.6–49.0)	−0.15	44.9 (43.2–46.5)	47.2 (45.5–48.9)	0.26
Student	65	51.6 (50.1–53.0)	52.3 (51.0–53.6)	0.12	47.0 (44.6–49.4)	49.7 (47.6–51.8)	0.41
Unemployed	36	52.2 (50.5–53.9)	51.1 (49.5–52.7)	−0.16	43.9 (41.1–46.7)	48.7 (46.3–51.0)
Systemic diseases
No	933	51.3 (50.9–51.7)	51.0 (50.6–51.5)	−0.04	48.5(47.9– 49.2)	50.6 (50.0–51.3)	0.20
Yes	249	49.1 (48.1–50.0)	47.5 (46.4–48.5)	−0.21	48.1 (46.8–49.5)	49.6 (48.1–51.0)	0.13
Unreported	41
Clinical indications
Ectasia/thinning	721	51.7 (51.2–52.1)	51.3 (50.8–51.7)	−0.07	48.4 (47.6–49.1)	50.7 (50.0–51.4)	0.23
All other indications	502	49.5 (48.9–50.2)	48.7 (48.0–49.4)	−0.12	48.4 (47.6–49.1)	50.1 (49.0–51.1)	0.14
Previous keratoplasties
No	1,020	50.9 (50.5–51.3)	50.3 (49.8–50.7)	−0.09	48.3 (47.7–49.0)	50.5 (49.8–51.1)	0.20
Yes	148	50.1 (48.9–51.3)	49.4 (48.1–50.6)	−0.09	48.4 (46.5–50.2)	49.5 (47.6–51.5)	0.10
Unreported	55
Previous ocular surgery (other than graft)
No	884	51.5 (51.0–51.9)	50.8 (50.4–51.3)	−0.10	48.2 (47.5–48.9)	50.5 (49.8–51.1)	0.22
Yes	284	48.8 (47.9–49.6)	48.1 (47.0–49.1)	−0.09	48.9 (47.5–50.2)	50.1 (48.7–51.5)	0.10
Unreported	55
Other ocular diseases
No	939	51.0 (50.6–51.5)	50.6 (50.1–51.0)	−0.07	48.0 (47.4–48.7)	50.2 (49.6–51.0)	0.20
Yes	257	50.0 (49.1–50.9)	49.1 (48.2–50.1)	−0.12	49.4 (48.1–50.7)	51.0 (49.7–52.3)	0.15
Unreported	27
Adverse reactions/complications (follow-up)
No	809	50.9 (50.4–51.4)	50.7 (50.3–51.2)	−0.02	48.7 (48.0–49.4)	50.9 (50.2–51.6)	0.21
Yes	188	51.6 (50.6–52.5)	49.9 (48.8–51.0)	−0.24	47.3 (45.8–48.7)	48.9 (47.3–50.6)	0.16
Unreported	226
BCVA^§ (at baseline)
≤2/10	922	50.7 (50.3–51.2)	50.4 (49.6–50.5)	−0.10	48.5 (47.9–49.2)	50.6 (49.9–51.3)	0.20
3/10-4/10	188	50.8 (49.9–51.7)	51.1 (50.2–52.0)	0.04	48.6 (47.1–50.1)	49.8 (48.2–51.3)	0.11
5/10-7/10	76	51.7 (50.1–53.4)	50.4 (48.8–52.0)	−0.18	46.8 (44.0–49.6)	50.7 (48.4–52.9)	0.31
≥8/10	5	52.1 (43.3–60.9)	47.7 (37.5–57.9)	−0.62	50.9 (34.4–67.3)	55.9 (48.1–63.7)	0.38
Unreported	32

*Negative values of ES indicate poorer SF-12 scores compared to baseline; ^§best corrected visual acuity.